Skip to main content
Erschienen in: Osteoporosis International 9/2008

01.09.2008 | Original Article

Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study

verfasst von: H. A. Fink, M. A. Kuskowski, B. C. Taylor, J. T. Schousboe, E. S. Orwoll, K. E. Ensrud, for the Osteoporotic Fractures in Men (MrOS) Study Group

Erschienen in: Osteoporosis International | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Summary

Among community-dwelling older men, compared to those without Parkinson’s disease (PD), over approximately 5 years, those with baseline PD had a significantly greater rate of annualized total hip bone loss (−1.1% vs. 0.4%), proportion of incident non-spine fractures (14.9% vs. 7.2%) and mortality (34.8% vs. 9.5%).

Introduction

The objective of this study was to examine the association of Parkinson’s disease (PD) with bone loss and fractures in older men.

Methods

This prospective cohort study analyzed data from 5,937 community dwelling men aged ≥65 years at six clinical centers of the Osteoporotic Fractures in Men (MrOS) Study. At baseline and visit two (mean interval 4.6 +/−0.4 SD years), community-diagnosed PD was ascertained by self-report and hip bone mineral density (BMD) was measured using dual energy x-ray absorptiometry (DXA). Incident fractures were self-reported. Fractures and deaths were centrally adjudicated.

Results

At baseline, 46 (0.8%) men had PD. Age-adjusted mean annualized total hip bone loss was greater in men with vs. those without PD (−1.08% vs. −0.36%, p < 0.001). 15.2% of men with PD and 7.2% of men without PD experienced an incident non-spine fracture (age-adjusted HR 2.4, 95%CI 1.1–5.0). 34.8% of men with PD and 9.5% of men without PD died during follow-up (age-adjusted HR 3.5, 95%CI 2.2–5.5). Associations of PD with bone loss, fractures and mortality were modestly altered by additional individual adjustment for possible confounders.

Conclusions

In community-dwelling older men, PD was associated with increased bone loss, fractures and mortality. In addition to implementing fall prevention measures, clinicians should consider osteoporosis screening in older men with PD.
Literatur
1.
Zurück zum Zitat Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278PubMed Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278PubMed
2.
Zurück zum Zitat Taggart H, Crawford V (1995) Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing 24:326–328PubMedCrossRef Taggart H, Crawford V (1995) Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing 24:326–328PubMedCrossRef
3.
Zurück zum Zitat Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH (1994) Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun 15:173–177PubMedCrossRef Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH (1994) Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun 15:173–177PubMedCrossRef
4.
Zurück zum Zitat Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE (2005) Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 53:1559–1564PubMedCrossRef Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE (2005) Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 53:1559–1564PubMedCrossRef
5.
Zurück zum Zitat Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis D by 1alpha- hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68PubMedCrossRef Sato Y, Manabe S, Kuno H, Oizumi K (1999) Amelioration of osteopenia and hypovitaminosis D by 1alpha- hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 66:64–68PubMedCrossRef
6.
Zurück zum Zitat Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 31:114–118PubMedCrossRef Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 31:114–118PubMedCrossRef
7.
Zurück zum Zitat Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRef Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRef
8.
Zurück zum Zitat Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O’Brien LA, Hoffman S, Kaplan F (1991) Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 324:1326–1331PubMedCrossRef Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O’Brien LA, Hoffman S, Kaplan F (1991) Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 324:1326–1331PubMedCrossRef
9.
Zurück zum Zitat Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRef Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRef
10.
Zurück zum Zitat Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE (2004) Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479–1486PubMedCrossRef Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE (2004) Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479–1486PubMedCrossRef
11.
Zurück zum Zitat Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, Delay RR (2005) Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 26:557–568PubMedCrossRef Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, Delay RR (2005) Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials 26:557–568PubMedCrossRef
12.
Zurück zum Zitat Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRef Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRef
13.
Zurück zum Zitat Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153–162PubMedCrossRef Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153–162PubMedCrossRef
14.
Zurück zum Zitat Drugs for Parkinson’s disease (2007) Treat Guidel Med Lett 5:89–94 Drugs for Parkinson’s disease (2007) Treat Guidel Med Lett 5:89–94
15.
Zurück zum Zitat Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRef Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMedCrossRef
16.
Zurück zum Zitat Hamilton A, Balnave R, Adams R (1994) Grip strength testing reliability. J Hand Ther 7:163–170PubMed Hamilton A, Balnave R, Adams R (1994) Grip strength testing reliability. J Hand Ther 7:163–170PubMed
17.
Zurück zum Zitat Nevitt MC, Cummings SR, Kidd S, Black D (1989) Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 261:2663–2668 Nevitt MC, Cummings SR, Kidd S, Black D (1989) Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 261:2663–2668
18.
Zurück zum Zitat Bassey EJ, Short AH (1990) A new method for measuring power output in a single leg extension: feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol 60:385–390PubMedCrossRef Bassey EJ, Short AH (1990) A new method for measuring power output in a single leg extension: feasibility, reliability and validity. Eur J Appl Physiol Occup Physiol 60:385–390PubMedCrossRef
19.
Zurück zum Zitat Eng ML, Lyons KE, Pahwa R (2006) Prevalence of bone mineral density screening in Parkinson’s disease clinic outpatients. Mov Disord 21:2265–2266PubMedCrossRef Eng ML, Lyons KE, Pahwa R (2006) Prevalence of bone mineral density screening in Parkinson’s disease clinic outpatients. Mov Disord 21:2265–2266PubMedCrossRef
20.
Zurück zum Zitat Sato Y, Honda Y, Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911–915PubMedCrossRef Sato Y, Honda Y, Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911–915PubMedCrossRef
21.
Zurück zum Zitat Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929PubMedCrossRef Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929PubMedCrossRef
22.
Zurück zum Zitat Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ (2004) Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 26:436–442PubMedCrossRef Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ (2004) Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 26:436–442PubMedCrossRef
23.
Zurück zum Zitat Szulc P, Delmas PD (2007) Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos Int 18:495–503PubMedCrossRef Szulc P, Delmas PD (2007) Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos Int 18:495–503PubMedCrossRef
Metadaten
Titel
Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study
verfasst von
H. A. Fink
M. A. Kuskowski
B. C. Taylor
J. T. Schousboe
E. S. Orwoll
K. E. Ensrud
for the Osteoporotic Fractures in Men (MrOS) Study Group
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 9/2008
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0584-4

Weitere Artikel der Ausgabe 9/2008

Osteoporosis International 9/2008 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.